Saama Launches AI-Driven Data Platform
Suite of AI-enhanced SaaS solutions address many functions within clinical development.
Saama, a provider of AI- and ML-based solutions for clinical development and commercialization, announced its unified platform of SaaS-based products. By applying AI and advanced analytics to clinical development processes, Saama’s platform aims to eliminate manual, resource-intensive activities.
Saama uses more than 90 AI models built for life sciences, trained on over 300 million data points, which are embedded into the Saama platform. The platform includes the following solutions:
* Data Hub – to centralize and standardize clinical, operational, financial, and more data in a single location.
* Operational Insights – to provide a holistic view of trial operations to all team members and with visualizations of data including EDC, CTMS, and eTMF data.
* Patient Insights – to centralize and visualize patient data in a single location, and applies AI to patient data that can be used to predict patient behavior and track progress.
* Source to Submission (S2S) – automates the SDTM transformation process with AI/ML to simplify regulatory submissions.
* Smart Data Quality (SDQ) – automates data cleaning, review, and reconciliation processes for data managers to reduce query review.
Source: Saama Launches Industry’s First AI-driven Data Platform to Accelerate Clinical Development, June 20, 2023, BUSINESS WIRE.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
